FutureCeuticals Inc. announced publication of the results of another successful human clinical study on FruiteX-B® calcium fructoborate, a patented plant mineral complex.
The double-blind, placebo-controlled study examined the effects of FruiteX-B supplementation during 14 days on subjects with self-reported knee discomfort. The study population was equally divided between generally healthy men and women ranging in ages from 35 to 65. Testing measures included the widely-used WOMAC and McGill questionnaires, standard indices of joint and flex comfort. Analyses of effects were based upon the mean of within-subject changes from baseline values. Results showed that the effect of FruiteX-B was significantly more efficacious than the placebo.
In as little as seven days, subjects in the FruiteX-B group (30 subjects) experienced a 21 percent improvement in McGill scores (p=0.0025) and a trend toward improvement in WOMAC scores (25 percent reduction; p=0.06). At 14 days, subjects in the FruiteX-B group continued to see further significant improvement as measured by both McGill and WOMAC, 27 percent (p=0.0001) and 29 percent (p=0.0001) respectively. The placebo group (30 subjects) failed to show statistically significant differences. Statistics were independently reviewed by the Department of Statistics, School of Information and Computer Science, University of California at Irvine.
These results confirm results obtained from a previous study on the proprietary ingredient's fast-acting joint benefits, as measured by McGill and WOMAC, published in 2012.
This study represents one set of data from a broader clinical study on the joint and flex benefits of FruiteX-B calcium fructoborate. A second set of data on the ability of FruiteX-B to elicit substantially similar results when combined with glucosamine and chondroitin is currently under review.
"This new study extends our substantial body of peer-reviewed, published clinical work on the unique physiological benefits of FruiteX-B for joint health," said John M. Hunter, FutureCeuticals' executive vice president. "This extraordinary plant mineral complex continues to exhibit best-in-class clinical activity among lead ingredients in the joint space. Its "take-it, feel-it" benefits, combined with a small, affordable serving (108 mg twice daily), help explain why it has quickly become a key driver of the market's best joint/flex products. We couldn't be happier with these results."